Department of Defense Invests $1.3 Million to Study Cannabinoid for Symptoms of Autism
Autism spectrum disorder (ASD), is a developmental and behavioral disorder that affects human communication and behavior. One in 68 children have ASD and there are limited treatment options. The agents available (such as antipsychotics) have a number worrisome of side effects that limit their use.
The disorder also affects military readiness which is why the department of defense is interested in improving treatment.
A cannabinoid called Cannabidivarin (CBDV) may help treat symptoms such as irritability and repetitive behavior that are common in ASD. CBDV is a homolog of CBD, meaning it is closely chemically related (differs only by the presence of one methylene group).
The study will be conducted at Montefiore Health System in New York City, and will be led by Eric Hollander MD, a psychiatrist and Director of the Autism and Obsessive-Compulsive Spectrum Program at Montefiore Medical Center.